John Fox

Targeting glycosylated PD-1 induces potent antitumor immunity

March 20, 2020

Targeting glycosylated PD-1 immune checkpoint may be a promising new cancer immunotherapeutic strategy, according to a collaborative study led by Taiwanese researchers, which was reported online in the March 10, 2020, edition of Cancer Research.

Feisty old folks

Sprightly genomes bring insights into healthy aging, early-onset illness

Jan. 28, 2020

By John Fox

Australian researchers led by the Garvan Institute of Medical Research in Sydney have compiled the first reference genome database of healthy older Australians, which potentially can predict disease-linked gene variants more accurately than has been previously possible.

Bringing glaucoma risk into focus

Multitrait analysis predicts glaucoma susceptibility, progression

Jan. 28, 2020

By John Fox

An international collaborative study led by geneticists at the Queensland Institute of Medical Research Berghofer Medical Research Institute (QIMR) in Brisbane, Australia, has used a multivariate approach to develop a polygenic risk score (PRS) for glaucoma.

Bringing glaucoma risk into focus

Multitrait analysis predicts glaucoma susceptibility, progression

Jan. 24, 2020

By John Fox

An international collaborative study led by geneticists at the Queensland Institute of Medical Research Berghofer Medical Research Institute (QIMR) in Brisbane, Australia, has used a multivariate approach to develop a polygenic risk score (PRS) for glaucoma.

Another role for HIF-2a

Glutamine transporter variant identified as new cancer target

Jan. 7, 2020

By John Fox

A mitochondrial glutamine transporter variant is a key regulator of glutamine metabolism and metabolic reprogramming in cancer cells, and targeting such transporters could be a new strategy for controlling tumor growth.

Pick your poison

Cobra genome may yield new antivenoms, venom-based drugs

Jan. 7, 2020

By John Fox

A reference genome from the Indian cobra compiled in an international collaborative study should lead to the development of new safer and more effective antivenoms, while the elucidated genome and predicted associated proteome may be a powerful platform for studies of venomous snakes.

Glutamine transporter variant identified as new cancer target

Jan. 7, 2020

By John Fox

A mitochondrial glutamine transporter variant of the SLC1A5 gene is a key regulator of glutamine metabolism and metabolic reprogramming in cancer cells, and targeting such transporters could be a new strategy for controlling tumor growth, Korean researchers reported online in the Dec. 19, 2019, edition of Cell Metabolism.

Pick your poison

Cobra genome may yield new antivenoms, venom-based drugs

Jan. 6, 2020

By John Fox

A reference genome from the Indian cobra compiled in an international collaborative study should lead to the development of new safer and more effective antivenoms, while the elucidated genome and predicted associated proteome may be a powerful platform for studies of venomous snakes.

Another role for HIF-2a

Glutamine transporter variant identified as new cancer target

Jan. 3, 2020

By John Fox

A mitochondrial glutamine transporter variant is a key regulator of glutamine metabolism and metabolic reprogramming in cancer cells, and targeting such transporters could be a new strategy for controlling tumor growth, Korean researchers reported online in the Dec. 19, 2019, edition of Cell Metabolism.

Scientists report insights into the mechanics, literally, of IPF

Dec. 24, 2019

By John Fox

A Chinese study has established a previously unknown direct mechanistic link between elevated mechanical tension caused by impaired alveolar regeneration and progressive idiopathic pulmonary fibrosis (IPF), highlighting a pathogenic mechanism that may underlie fibrosis.

Articles by John Fox

Targeting glycosylated PD-1 induces potent antitumor immunity

Sprightly genomes bring insights into healthy aging, early-onset illness

Multitrait analysis predicts glaucoma susceptibility, progression

Multitrait analysis predicts glaucoma susceptibility, progression

Glutamine transporter variant identified as new cancer target

Cobra genome may yield new antivenoms, venom-based drugs

Glutamine transporter variant identified as new cancer target

Cobra genome may yield new antivenoms, venom-based drugs

Glutamine transporter variant identified as new cancer target

Scientists report insights into the mechanics, literally, of IPF

Today's news in brief

MMP inhibitors divulged in Accure Therapeutics patent

News in brief

Selective CBL-B inhibitor with improved safety profile disclosed

MSD discloses new HCN1/2 blockers